News
Vertex Pharmaceuticals is riding high on analyst confidence, thanks to its leadership in NAV1.8 inhibitors and smart partnerships. Jefferies analyst Michael Yee recently reaffirmed a Buy rating, ...
Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback